arrow
P

Paolo Sportoletti

University of Perugia and Santa Maria della Misericordia Hospital
H指数:36
被引数:7,236

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Rab GTPases drive ligand-independent NOTCH1 activation via altered endocytic trafficking in chronic lymphocytic leukemia

Rab GTP酶通过改变内吞转运驱动慢性淋巴细胞白血病中配体非依赖的NOTCH1激活

2026-07-290
OAAI
Neuroinflammatory changes in acute myeloid leukemia: Evidence for blood–brain barrier disruption and glial activation

急性髓系白血病中的神经炎症变化:血脑屏障破坏和胶质细胞激活的证据

2026-03-300
OAAI
Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI)

意大利前瞻性研究(ROMEI)中,IPSS中危-1风险骨髓纤维化患者接受鲁索利替尼治疗的临床结果:中期分析

2026-03-250
OAAI
Exploring the administrative burden faced by hematologists: a comprehensive study in Italy (vol 11, pg 161, 2024)

探索血液学家面临的管理负担:一项在意大利进行的综合研究(卷 11,页 161,2024)

2026-02-020
OAAI
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results

伊马替尼治疗慢性粒细胞白血病两次尼洛替尼巩固治疗后的无治疗缓解: 3期ENESTPath结果

Leukemia
IF13.4
2026-01-190
PRE
Rethinking the feasibility and safety of venetoclax-obinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice

重新思考维奈克拉-奥滨尤妥珠单抗在慢性淋巴细胞白血病中的可行性与安全性:非传统因素可能在临床实践中发挥作用

2026-01-014
OA
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Al-Sawaf, O.; Stumpf, J.; Zhang, C.; Simon, F.; Bosch, F.; Feyzi, E.; Ghia, P.; Gregor, M.; Kater, A.P.; Lindström, V.; 等. 固定疗程与持续治疗在慢性淋巴细胞白血病中的应用比较. N. Engl. J. Med. 2025, 393, 24. [Google Scholar] [CrossRef]

2025-12-018
PRE
Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study

在Nilotinib减量后的慢性期慢性髓性白血病中的无治疗缓解:DANTE研究的96周更新

2025-08-080
OAAI
Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports

维奈克拉联合阿扎胞苷作为IDH2突变型急性髓系白血病(AML)对强化化疗耐药时的基因驱动桥接移植疗法:概念验证病例报告

2025-07-080
OAAI
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes

慢性淋巴细胞白血病患者接受伊布替尼治疗的弥漫性大b细胞淋巴瘤的Richter转化: 危险因素和结果

Leukemia
IF13.4
2025-06-250
OAAI
Familial forms of chronic lymphocytic leukemia have a worse prognosis than sporadic forms: an Italian case-control study

家族性慢性淋巴细胞白血病比散发性形式的预后更差:一项意大利病例对照研究

2025-06-140
OAAI
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort

基于维奈克拉茨方案的八旬慢性淋巴细胞白血病患者:疗效、安全性及与BTKi的比较(多中心队列研究)

2025-04-240
OA
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice

Bcor基因缺失促进与Notch1激活相关的慢性淋巴细胞白血病向Richter转化的发生(小鼠模型)。

LEUKEMIA
IF13.4
2025-03-200
OA
The landscape of BRAF transcript and protein variants in human cancer (vol 16, 85 2017)

人类癌症中BRAF转录本和蛋白质变体的景观(vol 16, 85 2017)

2025-02-030
OA
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience
2025-01-140
OAAI
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience
2024-11-280
OAAI
CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or TP53 Mutations

CRISTALLO:一项关于Venetoclax-Obinutuzumab与Fludarabine、Cyclophosphamide和Rituximab或Bendamustine-Rituximab治疗无Del(17p)或TP53突变初治慢性淋巴细胞白血病患者Ⅲ期试验的结果

BLOOD
IF23.1
2024-11-050
PRE
Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

来自Arise研究(一项评估阿卡替尼在慢性淋巴细胞白血病(CLL)患者真实世界治疗中应用的意大利非干预性研究)的基线特征

BLOOD
IF23.1
2024-11-050
PRE
Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Patients with Newly Diagnosed Chronic Myeloid Leukemia Aged 50-60 Years: A Campus CML Study

基线特征、治疗选择及早期一线TKI永久停药在50-60岁新诊断慢性髓性白血病患者中的研究:一项Campus CML研究

BLOOD
IF23.1
2024-11-050
PRE